Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.333 EUR | +1.88% | +10.90% | +63.64% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.58 for the 2024 fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+63.64% | 198M | - | ||
-4.59% | 1.42B | - | ||
+56.98% | 558M | - | ||
-9.55% | 444M | - | ||
-3.20% | 94.66M | - | - | |
-23.03% | 81.6M | - | ||
+31.25% | 60.4M | - | C | |
+35.96% | 55.06M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- HITI Stock
- 2LYA Stock
- Ratings High Tide Inc.